Marrowforums

Marrowforums (http://forums.marrowforums.org/index.php)
-   Drugs and Drug Treatments (http://forums.marrowforums.org/forumdisplay.php?f=12)
-   -   FDA Medwatch Warning on CellCept, have you seen this yet? (http://forums.marrowforums.org/showthread.php?t=645)

adhddrugatrocity Mon Jun 30, 2008 06:43 PM

FDA Medwatch Warning on CellCept, have you seen this yet?
 
CellCept (mycophenolate mofetil)
Myfortic (mycophenolate acid)

Audience: Transplantation specialists, infectious disease specialists, other healthcare professionals
[UPDATE 6/26/08] Roche Laboratories informed healthcare professionals of changes to the WARNINGS and ADVERSE REACTIONS sections of the CellCept prescribing information. The changes are based on postmarketing data regarding cases of Progressive Multifocal Leukoencephalopathy (PML) in patients treated with CellCept.

[Posted 04/10/2008] FDA informed healthcare professionals that the Agency is investigating a potential association between the use of CellCept and Myfortic, medicines used to prevent organ rejection, and the development of progressive multifocal leukoencephalopathy (PML), a life-threatening disease. PML is a rare disorder that affects the central nervous system usually occurring in patients with immune systems suppressed by disease or medicines. FDA is reviewing data submitted by Roche, including postmarketing reports it has received of PML in patients who took CellCept or Myfortic, and the proposed revisions to the CellCept prescribing information. FDA has asked Novartis, the maker of Myfortic, for data on PML cases and to revise the Myfortic prescribing information to include the same information about PML included in the CellCept prescribing information. FDA anticipates it may take about 2 months to complete its review of the postmarketing reports and the proposed revisions to the prescribing information. As soon as the review is completed, FDA will communicate the conclusions and recommendations to the public.
Until further information is available, patients and healthcare professionals should be aware of the possibility of PML, such as localized neurologic signs and symptoms in the setting of a suppressed immune system, including during therapy with CellCept and Myfortic.

[June 2008 -- Dear Healthcare Professional Letter - Roche]
[April 10, 2008 - Communication About an Ongoing Safety Review - FDA]

Previous MedWatch Alerts:

[11/27/2007]
[10/29/2007]
[02/22/2007]


Return to Top | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact MedWatch


All times are GMT -4. The time now is 09:57 AM.

Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2021, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright 2006-2020 Marrowforums.org